The Alzheimer's Drugs Market forecast can help stakeholders in this marketplace plan their growth strategies. The market is projected to grow from US$ 6.21 billion in 2022 to US$ 22.01 billion by 2030; it is projected to register a CAGR of 17.1% during 2022-2030.

Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease.

Market Drivers Affecting Alzheimer's Drugs Market

The growing cases of AD and related dementia propel the Alzheimer's drugs market size. Alzheimer's disease is the most common form of dementia worldwide, accounting for 60-70% of all cases. It is a progressive neurodegenerative disease that worsens gradually over the years and is more common in the aging population. As per the World Health Organization (WHO) report published in October 2022, the global population aged 60 years and above will grow to 1.4 billion by 2030 and reach 2.1 billion by 2050. This growing geriatric population is anticipated to increase the disease burden, facilitating the demand for related medical treatments in the coming years.

Furthermore, rising awareness about AD, improving diagnosis rates, and increasing investments in the development of new treatments are the growth enablers of the market. According to a report published by the Alzheimer's Association in 2021, US$ 63 million was invested by the association in 2020 to advance Alzheimer's and dementia research.

Emerging Market Trends:

The rapid progression of Alzheimer's disease (AD) poses a serious threat to the global healthcare system. Additionally, the high failure rate of current therapies exacerbates the problem. It is predicted that the prevalence of this disorder will increase by four times by 2050, which will put tremendous economic pressure on the medical sector worldwide. Therefore, there is an urgent need to replace traditional approaches and adopt new disease prevention, treatment, and diagnosis methods. Precision medicine is a personalized approach to disease management that considers genetic variability, biomarker profiles, environmental influences, lifestyle factors, and the stage of the disease to develop patient-specific therapeutic interventions. Many studies are being carried out to understand the complex nature of the disease, which has led to the development of biomarker-guided treatment as a precision medicine approach. For instance, in an article published by medRxiv in 2021, a pilot scale clinical trial was carried out to evaluate a precision medicine strategy, which involves identifying and treating the potential causes of cognitive decline in Alzheimer's disease and mild cognitive impairment (MCI). The study concluded that a precision medicine approach for cognitive decline in Alzheimer's disease and MCI would be an effective strategy, especially when continued over time.

Alzheimer's Drugs Market Analysis based on the Segmental Share:

Based on drug class, the market is subsegmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment accounted for the largest Alzheimer's drugs market share in 2022 and is estimated to register the highest CAGR during 2022-2030. Based on drug class, the cholinesterase inhibitors segment is further segmented into donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors are prescribed by specialists such as psychiatrists or neurologists for early- to mid-stage AD. These drugs boost the levels of acetylcholine in the brain, a neurotransmitter that helps nerve cells communicate with each other.

By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held the largest market share. Online pharmacies segment is anticipated to register the highest CAGR during 2022-2030.

Regional Sternal Closure System Market Analysis:

In terms of revenue, North America dominated the Alzheimer's drugs market share. In 2022, North America held the largest share of the global market owing to pharmaceutical companies' extensive research and development activities, and the prevalence of AD and associated dementia in the aging population. According to the Alzheimer's Association, in 2023, over 6 million people in America were diagnosed with AD, and ~1 in 9 individuals aged 65 years or above-representing 10.7% of the American population-were affected by Alzheimer's. Additionally, according to statistics provided by the Centers for Disease Control and Prevention (CDC) in October 2020, AD is the sixth leading cause of death among US adults. Furthermore, the increasing spending on healthcare services across the US boosts the demand for AD treatment drugs, augmenting the Alzheimer's drugs market growth in the region.